Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00661999 · OUTCOME

C-reactive Protein (CRP) Level at Week 1, Week 7 and Week 16

Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer · Source last updated 2011-05-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
mg/L
Interval / dispersion
Standard Deviation
Time frame
1 Week, 7 Weeks and 16 Weeks

Groups in this outcome

DA + IV Iron

Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.

DA + Oral Iron

Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.

DA + Placebo

Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
DA + IV Iron164
DA + Oral Iron163
DA + Placebo163

Reported measurements

Week 1
Values in mg/L · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
DA + IV Iron24.838.12Not reportedNot reportedNot reported
DA + Oral Iron25.436.36Not reportedNot reportedNot reported
DA + Placebo31.658.68Not reportedNot reportedNot reported
Week 7
Values in mg/L · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
DA + IV Iron28.651.09Not reportedNot reportedNot reported
DA + Oral Iron16.625.25Not reportedNot reportedNot reported
DA + Placebo27.049.20Not reportedNot reportedNot reported
Week 16
Values in mg/L · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
DA + IV Iron25.646.30Not reportedNot reportedNot reported
DA + Oral Iron16.736.98Not reportedNot reportedNot reported
DA + Placebo21.239.07Not reportedNot reportedNot reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Pct Value
    95
    group Ids
    1. OG000
    2. OG001
    3. OG002
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    p Value
    0.3852
    p Value Comment
    Test Comparison for Week 1 Level
    statistical Method
    Kruskal-Wallis
    tested Non Inferiority
    false
  2. ci Pct Value
    95
    group Ids
    1. OG000
    2. OG001
    3. OG002
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    p Value
    0.0663
    p Value Comment
    Test Comparison for Week 7 Level.
    statistical Method
    Kruskal-Wallis
    tested Non Inferiority
    false
  3. ci Pct Value
    95
    group Ids
    1. OG000
    2. OG001
    3. OG002
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    p Value
    0.3220
    p Value Comment
    Test Comparison for Week 16 Level
    statistical Method
    Kruskal-Wallis
    tested Non Inferiority
    false
Complete source fields
analyses
  1. ci Pct Value
    95
    group Ids
    1. OG000
    2. OG001
    3. OG002
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    p Value
    0.3852
    p Value Comment
    Test Comparison for Week 1 Level
    statistical Method
    Kruskal-Wallis
    tested Non Inferiority
    false
  2. ci Pct Value
    95
    group Ids
    1. OG000
    2. OG001
    3. OG002
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    p Value
    0.0663
    p Value Comment
    Test Comparison for Week 7 Level.
    statistical Method
    Kruskal-Wallis
    tested Non Inferiority
    false
  3. ci Pct Value
    95
    group Ids
    1. OG000
    2. OG001
    3. OG002
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    p Value
    0.3220
    p Value Comment
    Test Comparison for Week 16 Level
    statistical Method
    Kruskal-Wallis
    tested Non Inferiority
    false
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        38.12
        value
        24.8
      2. group Id
        OG001
        spread
        36.36
        value
        25.4
      3. group Id
        OG002
        spread
        58.68
        value
        31.6
    title
    Week 1
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        51.09
        value
        28.6
      2. group Id
        OG001
        spread
        25.25
        value
        16.6
      3. group Id
        OG002
        spread
        49.20
        value
        27.0
    title
    Week 7
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        46.30
        value
        25.6
      2. group Id
        OG001
        spread
        36.98
        value
        16.7
      3. group Id
        OG002
        spread
        39.07
        value
        21.2
    title
    Week 16
denoms
  1. counts
    1. group Id
      OG000
      value
      164
    2. group Id
      OG001
      value
      163
    3. group Id
      OG002
      value
      163
    units
    Participants
dispersion Type
Standard Deviation
groups
  1. description
    Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
    id
    OG000
    title
    DA + IV Iron
  2. description
    Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
    id
    OG001
    title
    DA + Oral Iron
  3. description
    Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
    id
    OG002
    title
    DA + Placebo
param Type
MEAN
reporting Status
POSTED
time Frame
1 Week, 7 Weeks and 16 Weeks
title
C-reactive Protein (CRP) Level at Week 1, Week 7 and Week 16
type
SECONDARY
unit Of Measure
mg/L

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice